ClinicalTrials.gg
RecruitingNCT06663358MODERNUpdated Nov 14, 2025

A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients

An observational study in Fabry Disease, sponsored by Chiesi Farmaceutici S.p.A.. Recruiting at 10 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-14.

Sponsored by Chiesi Farmaceutici S.p.A. · Observational

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Fabry Disease by Chiesi Farmaceutici S.p.A. — 5 open to participants now, 5 under way, 2 of them phase 3. Fabry Disease · Chiesi Farmaceutici S.p.A..

Started
2024
the only one that year
Observational
5 of 10
3 open now
Registered
8th of 10
by date

Among the 10 studies in Fabry Disease by Chiesi Farmaceutici S.p.A., this one is the only one that started in 2024, is one of 5 observational ones, and was the 8th registered.

Fabry Disease

244 studies on the registry are indexed under Fabry Disease; 54 are open to participants now.

Browse Fabry Disease studies →

Open to participants now

5 of the 10 studies in Fabry Disease by Chiesi Farmaceutici S.p.A. are open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 44 Fabry Disease studies recruiting now, 31 (70%) set no upper age limit and 11 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Fabry Disease by Chiesi Farmaceutici S.p.A., or all of them as a file.
02

Study summary

A multi-centre, multi-country, observational, non-interventional, retrospective and prospective (hybrid) study among Fabry disease participants treated with pegunigalsidase alfa (Elfabrio®) in routine clinical care.

03

Conditions studied

  • Fabry Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The eligible population for this study includes participants who have a genetically confirmed diagnosis of Fabry disease and are being treated or plan to initiate treatment with pegunigalsidase alfa (Elfabrio®). Participants will be required to meet inclusion, not meet exclusion criteria and sign informed consent to be enrolled in the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged > 18 years of age at the time of consent.
  • Genetically confirmed diagnosis of Fabry disease.
  • Either taking or planning to take pegunigalsidase alfa as treatment for Fabry disease.
  • No for cardiac magnetic resonance imaging (cMRI)
  • form (ICF) signed and dated indicating the individual has been informed of and agreed to all pertinent aspects of the study and is willing to comply with all study requirements, including completion of electronic patient reported outcomes (ePROs).
  • Cardiac Cohort:
  • Evidence of Fabry disease (FD)-related heart disease including one or more of the following:
  • Left ventricular hypertrophy (LVH) measured by left ventricular mass index (LVMI) (g/m2) elevation above age/sex specific reference ranges.
  • Posterior septum wall thickness (e.g., >=13mm) not explained by other factors (e.g., hypertension)
  • Low native T1 mapping on cMRI.
  • Typical Fabry-like scar on cMRI
  • Participants can receive cardiac magnetic resonance imaging (cMRI) with gadolinium enhancement as part of their SoC.
  • Estimated (eGFR) >45 mL/min/1.73 m2, assessed within the prior 6 months.
  • Naïve Cohort:
  • Most recent eGFR>45 mL/min/1.73 m2, assessed within prior 6 months.
  • Male participants should have abnormal elevation in plasma lysoGb3 as assessed within 6 months prior to enrolment.
  • Long-Term Cohort:
  • Participants previously enrolled in the open label study CLI-06657AA1-04 (Previously PB-102-F60) (using pegunigalsidase alfa at a dose of 1mg/kg every 2 weeks) who have initiated or plan to initiate commercial pegunigalsidase alfa (Elfabrio®).

Exclusion criteria

Exclusion Criteria:

  • to magnetic resonance imaging (MRI) including known history of to gadolinium contrast agent that is not managed by the use of premedication.
  • Pregnant at the time of enrolment.
  • Presence of any medical, emotional, behavioural, or psychological condition that, in the judgment of the physician, could interfere with the ability to participate in the study.
  • Active participation in any interventional study for Fabry disease
  • Treatment regimen at the time of enrolment in the study is different from the approved 1mg/kg every two weeks (note if regimen subsequently changes during the prospective part of the study, the participants can remain in the study)
  • Prior participation in a pegunigalsidase alfa trial using a dose of 2 mg/kg administered every 4 weeks.
  • Cardiac Cohort:
  • History of acute myocardial infarction or congestive heart failure with reduced left ventricular (LV) of less than 35%.
  • Cerebral vascular accident (CVA) in the prior 6 months.
  • Chronic liver cirrhosis.
  • FD-unrelated heart disease (e.g., scarring due to myocardial infarction, symptomatic occlusive coronary artery disease, moderate valvular heart disease not thought to be Fabry related).
  • The participant is or has been treated with any drug for Fabry disease within 6 months of study start or investigational gene therapy for Fabry disease at any time point in the past.
  • Severe cardiac fibrosis defined as more than 3 segments that each have >50% fibrosis upon late gadolinium enhancement cMRI at any prior cMRI.
  • Naïve Cohort:
  • Prior exposure to a FD therapy (Replagal®, Fabrazyme®, and Galafold®) at any time point.
  • Severe cardiac fibrosis defined as more than 3 segments that each have >50% fibrosis upon late gadolinium enhancement cMRI on any prior cMRI
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cardiac Cohort

    Patients with Fabry-related cardiac disease

    Drug: Pegunigalsidase-alfa

  • Naïve Cohort

    Patients naïve to prior Fabry disease treatment

    Drug: Pegunigalsidase-alfa

  • Long-Term Cohort

    Patients previously participating in the pegunigalsidase alfa open label extension study and transitioning to routine care

    Drug: Pegunigalsidase-alfa

Interventions

  • Administered via intravenous (IV) infusion under conditions of routine clinical care

    Also known as: Elfabrio®

06

What researchers measure

Primary outcomes

  1. Estimated Glomerular Filtration Rate (eGFR)

    eGFR, calculated using the Chronic Kidney Disease - Epidemiology Collaboration (eGFRCKD-EPI) equation from study baseline and from pegunigalsidase alfa treatment start to end of follow-up and to pre-specified time points (annually).

    Time frame: 4 years

  2. Plasma Globotriaosylsphingosine (LysoGb3) Concentration

    Levels of the Fabry disease biomarker plasma globotriaosylsphingosine (lyso-Gb3) over time, and change from study baseline and from pegunigalsidase alfa treatment start to end of follow-up.

    Time frame: 4 years

  3. Left Ventricular Mass Index (LVMI; g/m2)

    Change in LVMI over time as assessed by cardiac MRI. Based on LVM indexed by height and/or body surface area.

    Time frame: 4 years

  4. High Sensitivity Troponin (hs-cTnT)

    Change in levels of hs-cTnT over time

    Time frame: 4 years

  5. Safety Assessments

    The endpoints will include occurrence of SAEs, infusion-related reactions (IRRs), drug-related adverse events, and proportion of participants with ADAs over time.

    Time frame: 4 years

07

Study locations

10 of 10 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Nov 2029, 60 months after the start.

Of 61 observational studies under Fabry Disease, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 36. This study's planned 60 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2024
First posted
Oct 29, 2024
StartActual
Nov 6, 2024
Primary completionEst.
Nov 2029
CompletionEst.
Nov 2029
Last update
Nov 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06663358
Responsible party
Sponsor
First posted
Oct 29, 2024
Start date
Nov 6, 2024
Primary completion
Nov 2029 (estimated)
Completion
Nov 2029 (estimated)
Last update
Nov 14, 2025

Study contacts

Medical Information Chiesi
Contact
us.medical@chiesi.com
(888) 661-9260

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion